GNH USA

Europe — EMA

Mycophenolate Mofetil Sandoz

GNH USA supplies Mycophenolate Mofetil Sandoz (Mycophenolate Mofetil), an immunosuppressant for preventing organ transplant rejection and treating lupus

Request sourcing

1
Pack/s

What is Mycophenolate Mofetil?

Mycophenolate Mofetil, the active ingredient in Mycophenolate Mofetil Sandoz, is an immunosuppressant presented as an oral tablet for oral use. It is used to prevent acute rejection in organ transplantation and to treat lupus nephritis in patients requiring immune modulation.

GNH USA supplies Mycophenolate Mofetil Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and pharmacies worldwide.

What is Mycophenolate Mofetil used for?

Mycophenolate Mofetil is employed in the management of immune‑mediated conditions, particularly in transplant and autoimmune settings.

- Prevention of acute organ transplant rejection: reduces the risk of graft rejection in kidney, heart and liver transplants. - Treatment of lupus nephritis: helps control renal inflammation in systemic lupus erythematosus. - Maintenance immunosuppression after transplantation: supports long‑term graft survival by sustaining immune suppression.

What are the side effects of Mycophenolate Mofetil?

Adverse reactions may range from mild to severe and should be monitored throughout therapy.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: frequent loose stools. - Headache: transient cranial discomfort. - Abdominal pain: cramping or discomfort in the stomach area. - Upper respiratory infections: increased susceptibility to colds and sinusitis.

Serious or Rare Side Effects: - Leukopenia: significant reduction in white blood cells. - Anemia: decreased red blood cell count leading to fatigue. - Severe infections: opportunistic infections such as pneumonia or sepsis. - Hepatic dysfunction: elevated liver enzymes or hepatitis. - Malignancy risk: potential increased risk of certain cancers with long‑term use. - Progressive multifocal leukoencephalopathy (PML): rare but life‑threatening brain infection.

What precautions apply to Mycophenolate Mofetil?

Patients receiving Mycophenolate Mofetil should be closely monitored for safety and efficacy. - Monitor blood counts: regular CBC to detect leukopenia or anemia. - Assess renal function: adjust therapy if creatinine rises. - Check liver enzymes: watch for hepatic toxicity. - Avoid live vaccines: increased risk of vaccine‑derived infection. - Pregnancy and breastfeeding: safety unknown; discuss risks with a healthcare professional. - Store at below 25°C: keep in the original container, protect from moisture and light.

What does Mycophenolate Mofetil interact with?

Mycophenolate Mofetil can interact with several medicines, altering its effectiveness or safety.

Major Interactions (Avoid): - Azathioprine: additive bone‑marrow suppression may cause severe cytopenias. - Cyclosporine or tacrolimus: combined immunosuppression raises infection risk. - Live vaccines: heightened chance of vaccine‑derived disease.

Moderate Interactions (Monitor Closely): - Antacids containing aluminum or magnesium: may reduce absorption of mycophenolic acid. - Rifampin or other strong enzyme inducers: can lower drug levels, reducing efficacy.

Frequently asked questions

What conditions is Mycophenolate Mofetil Sandoz used for?+
Mycophenolate Mofetil Sandoz is indicated for the prevention of acute rejection in kidney, heart and liver transplantation, and for the treatment of lupus nephritis. It helps maintain graft function and control renal inflammation by suppressing the immune response.
How does Mycophenolate Mofetil work in the body?+
The drug is a pro‑drug that is converted to mycophenolic acid, which reversibly inhibits the enzyme inosine monophosphate dehydrogenase (IMPDH). This inhibition depletes guanosine nucleotides, selectively blocking the proliferation of T‑ and B‑lymphocytes and thereby reducing immune activity.
What is the usual dose of Mycophenolate Mofetil Sandoz?+
The specific dose and dosing schedule are determined by the prescribing clinician based on the patient’s condition, transplant type, renal function and other individual factors. Patients should follow the prescriber’s instructions and not adjust the dose on their own.
Is Mycophenolate Mofetil safe during pregnancy or breastfeeding?+
The safety of Mycophenolate Mofetil in pregnancy and lactation is not established. It is generally advised to avoid use during pregnancy unless the potential benefit justifies the risk, and to discuss breastfeeding considerations with a healthcare professional.
How do I order Mycophenolate Mofetil Sandoz from GNH USA?+
To place an order, submit an enquiry on the product page at gnh-usa.com, specifying the required quantity. GNH USA works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.
How does Mycophenolate Mofetil compare with other immunosuppressants?+
Mycophenolate Mofetil offers a distinct mechanism by inhibiting IMPDH, which differs from calcineurin inhibitors like cyclosporine. It is often used in combination with other agents to achieve synergistic immunosuppression while potentially offering a different side‑effect profile, such as lower nephrotoxicity compared with calcineurin inhibitors.
What are the recommended storage conditions for Mycophenolate Mofetil Sandoz?+
Store the tablets at temperatures below 25 °C, in the original packaging, protected from moisture and direct sunlight. Do not refrigerate or freeze the product, and keep it out of reach of children.
How is Mycophenolate Mofetil administered?+
Mycophenolate Mofetil Sandoz is taken orally, usually with food to reduce gastrointestinal discomfort. The tablets should be swallowed whole with a glass of water and not chewed or crushed unless specifically instructed by a healthcare provider.
What are the most serious risks associated with Mycophenolate Mofetil?+
Serious risks include severe infections due to immune suppression, leukopenia or anemia, liver toxicity, and rare but life‑threatening conditions such as progressive multifocal leukoencephalopathy (PML). Patients should be monitored regularly for these complications.
Who should not use Mycophenolate Mofetil?+
Patients with known hypersensitivity to mycophenolate mofetil or any component of the formulation should avoid the drug. It is also contraindicated in individuals receiving live vaccines or those with uncontrolled infections, and caution is advised in pregnant or breastfeeding women.
Information provided on this page is for educational use by procurement and clinical professionals. Always consult a licensed healthcare provider for medical advice and prescribing decisions. GNH USA supplies this product subject to applicable regulatory and licensing requirements.

Product details

Drug
Mycophenolate Mofetil
Route
Oral Use
Manufacturer
Sandoz
Origin
EU

Related products